Report of an international working group to standardize response criteria for myelodysplastic syndromes.

By B. Cheson, J. Bennett, H. Kantarjian, A. Pinto, C. Schiffer, S. Nimer, B. Löwenberg, M. Beran, T. Witte, R. Stone and 5 more. Blood, 2000

721 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. (2007, background): “Complications from cytopenias lead to higher morbidity and mortality among patients with MDS compared to an age-matched population.(9) The variable risk of progression to acute myeloid leukemia (AML) is of major prognostic significance in early MDS without blast excess.”
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. (2007, unknown): “of courses requiring hospitalization (%) 50 (12) 14 (14) 23 (23)”
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias (2012, unknown): “No mutations 18 (28) 13 (30) 4 (44) 1 (12) 0”
Decitabine improves patient outcomes in myelodysplastic syndromes (2006, background): “Clinical response Overall response (CR PR) 15 (17) 0 .”
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. (2006, methodology): “Thalidomide28 83 Low/Int1, 70; High/Int2, 30 13 (5) 0 (1) 0 Thalidomide29 29 RA, 14; RARS, 4; RAEB, 3; RAEB-t, 5; CMML, 3 10 (21) 14 (7) 3 (7) Arsenic trioxide20 101 Low/Int1, 39; High/Int2, 61 11 (0) 6 (0) 8 (0) Valproic acid30 18 Low, 17; Int1, 55; Int2, 17; High, 11 11 (0) 11 (0) 6 (0)”